Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas

N. Sadanaga, H. Nagashima, K. Mashino, K. Tahara, H. Yamaguchi, M. Ohta, T. Fujie, F. Tanaka, H. Inoue, K. Takesako, T. Akiyoshi, Masaki Mori

Research output: Contribution to journalArticle

179 Citations (Scopus)

Abstract

The MAGE gene is selectively expressed in cancer tissues such as melanoma or gastrointestinal carcinomas, whereas no expression is observed in normal tissues except testis. There are several reports of successful induction of HLA class I-restricted antitumor CTLs using MAGE peptides, and some clinical trials with these immunogenic peptides were reported as effective for some patients with malignant melanoma. However, there are no similar studies in gastrointestinal carcinomas, which are important neoplasms. Autologous dendritic cells (DCs) were generated ex vivo and were pulsed with MAGE-3 peptide, depending on the patient's HLA haplotype (HLA-A2 or A24). Patients were immunized with DC pulsed with MAGE-3 peptide every 3 weeks at four times. Twelve patients with advanced gastrointestinal carcinoma (six stomach, three esophagus, and three colon) were treated, and no toxic side effects were observed. Peptide-specific CTL responses after vaccination were observed in four of eight patients. Improvement in performance status was recognized in four patients. Tumor markers decreased in seven patients. In addition, minor tumor regressions evidenced by imaging studies were seen in three patients. These results suggested that DC vaccination with MAGE-3 peptide is a safe and promising approach in the treatment of gastrointestinal carcinomas.

Original languageEnglish
Pages (from-to)2277-2284
Number of pages8
JournalClinical Cancer Research
Volume7
Issue number8
Publication statusPublished - Aug 27 2001

Fingerprint

Dendritic Cells
Vaccination
Carcinoma
Peptides
Therapeutics
Melanoma
HLA-A24 Antigen
HLA-A2 Antigen
Neoplasms
Poisons
Tumor Biomarkers
Haplotypes
Esophagus
Testis
Stomach
Colon
Clinical Trials
Genes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Sadanaga, N., Nagashima, H., Mashino, K., Tahara, K., Yamaguchi, H., Ohta, M., ... Mori, M. (2001). Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clinical Cancer Research, 7(8), 2277-2284.

Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. / Sadanaga, N.; Nagashima, H.; Mashino, K.; Tahara, K.; Yamaguchi, H.; Ohta, M.; Fujie, T.; Tanaka, F.; Inoue, H.; Takesako, K.; Akiyoshi, T.; Mori, Masaki.

In: Clinical Cancer Research, Vol. 7, No. 8, 27.08.2001, p. 2277-2284.

Research output: Contribution to journalArticle

Sadanaga, N, Nagashima, H, Mashino, K, Tahara, K, Yamaguchi, H, Ohta, M, Fujie, T, Tanaka, F, Inoue, H, Takesako, K, Akiyoshi, T & Mori, M 2001, 'Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas', Clinical Cancer Research, vol. 7, no. 8, pp. 2277-2284.
Sadanaga N, Nagashima H, Mashino K, Tahara K, Yamaguchi H, Ohta M et al. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clinical Cancer Research. 2001 Aug 27;7(8):2277-2284.
Sadanaga, N. ; Nagashima, H. ; Mashino, K. ; Tahara, K. ; Yamaguchi, H. ; Ohta, M. ; Fujie, T. ; Tanaka, F. ; Inoue, H. ; Takesako, K. ; Akiyoshi, T. ; Mori, Masaki. / Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. In: Clinical Cancer Research. 2001 ; Vol. 7, No. 8. pp. 2277-2284.
@article{fb9a9195f0794c1b9dd5cfb00f916dc0,
title = "Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas",
abstract = "The MAGE gene is selectively expressed in cancer tissues such as melanoma or gastrointestinal carcinomas, whereas no expression is observed in normal tissues except testis. There are several reports of successful induction of HLA class I-restricted antitumor CTLs using MAGE peptides, and some clinical trials with these immunogenic peptides were reported as effective for some patients with malignant melanoma. However, there are no similar studies in gastrointestinal carcinomas, which are important neoplasms. Autologous dendritic cells (DCs) were generated ex vivo and were pulsed with MAGE-3 peptide, depending on the patient's HLA haplotype (HLA-A2 or A24). Patients were immunized with DC pulsed with MAGE-3 peptide every 3 weeks at four times. Twelve patients with advanced gastrointestinal carcinoma (six stomach, three esophagus, and three colon) were treated, and no toxic side effects were observed. Peptide-specific CTL responses after vaccination were observed in four of eight patients. Improvement in performance status was recognized in four patients. Tumor markers decreased in seven patients. In addition, minor tumor regressions evidenced by imaging studies were seen in three patients. These results suggested that DC vaccination with MAGE-3 peptide is a safe and promising approach in the treatment of gastrointestinal carcinomas.",
author = "N. Sadanaga and H. Nagashima and K. Mashino and K. Tahara and H. Yamaguchi and M. Ohta and T. Fujie and F. Tanaka and H. Inoue and K. Takesako and T. Akiyoshi and Masaki Mori",
year = "2001",
month = "8",
day = "27",
language = "English",
volume = "7",
pages = "2277--2284",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas

AU - Sadanaga, N.

AU - Nagashima, H.

AU - Mashino, K.

AU - Tahara, K.

AU - Yamaguchi, H.

AU - Ohta, M.

AU - Fujie, T.

AU - Tanaka, F.

AU - Inoue, H.

AU - Takesako, K.

AU - Akiyoshi, T.

AU - Mori, Masaki

PY - 2001/8/27

Y1 - 2001/8/27

N2 - The MAGE gene is selectively expressed in cancer tissues such as melanoma or gastrointestinal carcinomas, whereas no expression is observed in normal tissues except testis. There are several reports of successful induction of HLA class I-restricted antitumor CTLs using MAGE peptides, and some clinical trials with these immunogenic peptides were reported as effective for some patients with malignant melanoma. However, there are no similar studies in gastrointestinal carcinomas, which are important neoplasms. Autologous dendritic cells (DCs) were generated ex vivo and were pulsed with MAGE-3 peptide, depending on the patient's HLA haplotype (HLA-A2 or A24). Patients were immunized with DC pulsed with MAGE-3 peptide every 3 weeks at four times. Twelve patients with advanced gastrointestinal carcinoma (six stomach, three esophagus, and three colon) were treated, and no toxic side effects were observed. Peptide-specific CTL responses after vaccination were observed in four of eight patients. Improvement in performance status was recognized in four patients. Tumor markers decreased in seven patients. In addition, minor tumor regressions evidenced by imaging studies were seen in three patients. These results suggested that DC vaccination with MAGE-3 peptide is a safe and promising approach in the treatment of gastrointestinal carcinomas.

AB - The MAGE gene is selectively expressed in cancer tissues such as melanoma or gastrointestinal carcinomas, whereas no expression is observed in normal tissues except testis. There are several reports of successful induction of HLA class I-restricted antitumor CTLs using MAGE peptides, and some clinical trials with these immunogenic peptides were reported as effective for some patients with malignant melanoma. However, there are no similar studies in gastrointestinal carcinomas, which are important neoplasms. Autologous dendritic cells (DCs) were generated ex vivo and were pulsed with MAGE-3 peptide, depending on the patient's HLA haplotype (HLA-A2 or A24). Patients were immunized with DC pulsed with MAGE-3 peptide every 3 weeks at four times. Twelve patients with advanced gastrointestinal carcinoma (six stomach, three esophagus, and three colon) were treated, and no toxic side effects were observed. Peptide-specific CTL responses after vaccination were observed in four of eight patients. Improvement in performance status was recognized in four patients. Tumor markers decreased in seven patients. In addition, minor tumor regressions evidenced by imaging studies were seen in three patients. These results suggested that DC vaccination with MAGE-3 peptide is a safe and promising approach in the treatment of gastrointestinal carcinomas.

UR - http://www.scopus.com/inward/record.url?scp=0034880680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034880680&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 2277

EP - 2284

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 8

ER -